InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,566.59
(
-0.01%
)
US TECH 100
19,865.60
(
0.10%
)
Dow Jones
39,315.70
(
-0.15%
)
Brent Oil
85.35
(
-1.34%
)
Bitcoin
56,397.87
(
0.99%
)
Post# of 252515
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119989
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: miljenko post# 231076

Friday, 04/17/2020 3:50:37 PM

Friday, April 17, 2020 3:50:37 PM

Post# of 252515
VIR-2218 uses essentially the same RNAi modification as ABUS’ AB-729, according to Evaluate Vantage:

https://www.evaluate.com/vantage/articles/news/trial-results/vir-bids-enter-hepatitis-b-race

Reminder: ABUS’ share price crashed after reporting phase-1 data for AB-729 in late March (#msg-154597458, #msg-154612542), close to the low point of the broad market. Perhaps investors’ reaction would be more benign today.

Thanks for weighing in.

Disclosure: No position in ABUS or VIR; long ENTA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up